{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:55:23Z","timestamp":1791489323603,"version":"4.3.4"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Background and Aims:<\/jats:title>\n            <jats:p>Severe alcohol-associated hepatitis (AH) is rising in incidence with a high mortality burden. While corticosteroids are recommended for eligible patients with severe AH, no guidance exists for the timing of steroid initiation, tapering regimens, and surveillance of adverse events. We aim to systematically review these variables and provide evidence-based recommendations for the inpatient and outpatient management of severe AH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results:<\/jats:title>\n            <jats:p>We performed a literature search from inception to May 30, 2024, to include clinical trials published in full form and assessed the quality of evidence using the Cochrane Risk of Bias tool. Data were collected on the timing of initiation, rate, and complications following steroid therapy, and taper regimens in the setting of severe AH. Of 28 studies that fulfilled our inclusion criteria, the median time from admission to steroid initiation was 6.5 days. The most common steroid dosing regimen was prednisolone 40\u00a0mg daily for 28 days. Twenty-five studies containing 3196 subjects reported adverse events, with exactly 50% in the steroid arm and the other half in the comparison arm. Infections, gastrointestinal bleeds, and renal impairment were the most frequently reported adverse events. Most infections occurred within the first month of the study. A 2-week steroid taper was the most frequently reported regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We recommend taking up to a week to systematically and thoroughly evaluate patients before initiating steroids, and vigilant monitoring in the first month of treatment. We also recommend the lowest possible steroid exposure with a 2-week steroid taper and close outpatient follow-up.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/hep.0000000000001237","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:00:58Z","timestamp":1738080058000},"page":"1241-1255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials"],"prefix":"10.1097","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3243-4439","authenticated-orcid":false,"given":"Michael A.","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5733-558X","authenticated-orcid":false,"given":"Prisca","family":"Pungwe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0057-1838","authenticated-orcid":false,"given":"Lauren L.M.","family":"Comer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-7284","authenticated-orcid":false,"given":"Maya","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-3447","authenticated-orcid":false,"given":"Tzu-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-8426","authenticated-orcid":false,"given":"George","family":"Cholankeril","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3633-382X","authenticated-orcid":false,"given":"Kavish R.","family":"Patidar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Gastroenterology and Hepatology, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1742-0293","authenticated-orcid":false,"given":"Avegail G.","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Gastroenterology and Hepatology, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7620-573X","authenticated-orcid":false,"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-7799","authenticated-orcid":false,"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[{"name":"Liver Unit, Hospital Clinic Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS), Universitat Barcelona, Barelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9174-5670","authenticated-orcid":false,"given":"Sumeet K.","family":"Asrani","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan P.","family":"Arab","sequence":"additional","affiliation":[{"name":"Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile"},{"name":"Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6715-3966","authenticated-orcid":false,"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Gastroenterology and Hepatology, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-4020","authenticated-orcid":false,"given":"Ruben","family":"Hernaez","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine Residency Program, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Gastroenterology and Hepatology, Michael E DeBakey Veterans Affairs Medical Center, Houston, Texas, USA"},{"name":"Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"R1-20251017","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: Recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"R2-20251017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14309\/ajg.0000000000002572","article-title":"ACG Clinical Guideline: Alcohol-associated liver disease.","volume":"119","author":"Jophlin","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R3-20251017","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"R4-20251017","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: A randomized clinical trial","volume":"329","author":"Louvet","year":"2023","journal-title":"JAMA"},{"key":"R5-20251017","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2024.01.031","article-title":"Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis","volume":"80","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"R6-20251017","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/liv.12939","article-title":"Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: A meta-analysis of randomized trials","volume":"36","author":"Hmoud","year":"2016","journal-title":"Liver Int"},{"key":"R7-20251017","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","article-title":"Alcoholic hepatitis: Current challenges and future directions","volume":"12","author":"Singal","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20251017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2021.06.011","article-title":"Treatment of severe alcoholic hepatitis: A systematic review","volume":"60","author":"Van Melkebeke","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"R9-20251017","first-page":"152","article-title":"Infections in severe alcoholic hepatitis","volume":"30","author":"Karakike","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"R10-20251017","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"R11-20251017","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cld.736","article-title":"Steroids for severe alcoholic hepatitis: More risk than reward?","volume":"12","author":"Dao","year":"2019","journal-title":"Clin Liver Dis"},{"key":"R12-20251017","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2021.06.019","article-title":"Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study","volume":"75","author":"Arab","year":"2021","journal-title":"J Hepatol"},{"key":"R13-20251017","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical practice guidelines: Management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J Hepatol"},{"key":"R14-20251017","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Brit Med J"},{"key":"R15-20251017","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/apt.15376","article-title":"Systematic review with meta-analysis: High mortality in patients with non-severe alcoholic hepatitis","volume":"50","author":"Bennett","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20251017","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/gut.23.1.75","article-title":"Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis","volume":"23","author":"Theodossi","year":"1982","journal-title":"Gut"},{"key":"R17-20251017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12072-016-9751-4","article-title":"Prednisolone plus S-adenosil-l-methionine in severe alcoholic hepatitis","volume":"10","author":"Tkachenko","year":"2016","journal-title":"Hepatol Int"},{"key":"R18-20251017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J Hepatol"},{"key":"R19-20251017","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/hep.32478","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"76","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"R20-20251017","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJM199202203260802","article-title":"A randomized trial of prednisolone in patients with severe alcoholic hepatitis","volume":"326","author":"Ramond","year":"1992","journal-title":"N Engl J Med"},{"key":"R21-20251017","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197106172842404","article-title":"Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial","volume":"284","author":"Porter","year":"1971","journal-title":"N Engl J Med"},{"key":"R22-20251017","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis\u2014A randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J Hepatol"},{"key":"R23-20251017","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s10620-012-2097-4","article-title":"Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE Trial)","volume":"57","author":"Sidhu","year":"2012","journal-title":"Dig Dis Sci"},{"key":"R24-20251017","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM198412063112302","article-title":"Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone","volume":"311","author":"Mendenhall","year":"1984","journal-title":"N Engl J Med"},{"key":"R25-20251017","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2014.05.014","article-title":"Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: A randomised, non-inferiority, open trial","volume":"61","author":"Park","year":"2014","journal-title":"J Hepatol"},{"key":"R26-20251017","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2013.276300","article-title":"Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: A randomized clinical trial","volume":"310","author":"Mathurin","year":"2013","journal-title":"JAMA"},{"key":"R27-20251017","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"R28-20251017","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-74-3-311","article-title":"Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy","volume":"74","author":"Helman","year":"1971","journal-title":"Ann Intern Med"},{"key":"R29-20251017","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1053\/gast.1996.v110.pm8964410","article-title":"Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone","volume":"110","author":"Mathurin","year":"1996","journal-title":"Gastroenterology"},{"key":"R30-20251017","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0016-5085(80)90867-7","article-title":"Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy","volume":"78","author":"Depew","year":"1980","journal-title":"Gastroenterology"},{"key":"R31-20251017","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4103\/2141-9248.141562","article-title":"Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial","volume":"4","author":"De","year":"2014","journal-title":"Ann Med Health Sci Res"},{"key":"R32-20251017","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF01072499","article-title":"Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study","volume":"22","author":"Blitzer","year":"1977","journal-title":"Am J Dig Dis"},{"key":"R33-20251017","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3748\/wjg.15.1613","article-title":"Pentoxifylline versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial","volume":"15","author":"De","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R34-20251017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"R35-20251017","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-79-5-625","article-title":"Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial","volume":"79","author":"Campra","year":"1973","journal-title":"Ann Intern Med"},{"key":"R36-20251017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2000.8627","article-title":"Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial","volume":"32","author":"Cabr\u00e9","year":"2000","journal-title":"Hepatology"},{"key":"R37-20251017","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"R38-20251017","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: A randomized controlled pilot study","volume":"37","author":"Spahr","year":"2002","journal-title":"J Hepatol"},{"key":"R39-20251017","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: A randomized trial","volume":"17","author":"Pande","year":"2022","journal-title":"Hepatol Int"},{"key":"R40-20251017","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"key":"R41-20251017","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.cgh.2021.01.042","article-title":"Trajectory of serum bilirubin predicts spontaneous recovery in a real-world cohort of patients with alcoholic hepatitis","volume":"20","author":"Parker","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R42-20251017","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: A new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"R43-20251017","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: Early response to therapy is the key factor","volume":"137","author":"Louvet","year":"2009","journal-title":"Gastroenterology"},{"key":"R44-20251017","doi-asserted-by":"crossref","first-page":"e001419","DOI":"10.1136\/bmjoq-2021-001419","article-title":"Empowering patients: Simplifying discharge instructions","volume":"10","author":"Desai","year":"2021","journal-title":"BMJ Open Qual"},{"key":"R45-20251017","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/j.1742-1241.2010.02408.x","article-title":"Analysis of patient information leaflets provided by a district general hospital by the Flesch and Flesch-Kincaid method","volume":"64","author":"Williamson","year":"2010","journal-title":"Int J Clin Pract"},{"key":"R46-20251017","doi-asserted-by":"crossref","first-page":"100808","DOI":"10.1016\/j.jhepr.2023.100808","article-title":"Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis","volume":"5","author":"Incicco","year":"2023","journal-title":"JHEP Rep"},{"key":"R47-20251017","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2017.11.017","article-title":"Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis","volume":"68","author":"Forrest","year":"2018","journal-title":"J Hepatol"},{"key":"R48-20251017","doi-asserted-by":"crossref","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","article-title":"Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis","volume":"4","author":"Narum","year":"2014","journal-title":"BMJ Open"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000001237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:01:21Z","timestamp":1760695281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/hep.0000000000001237","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"2024-10-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}